The IMID Forum

Prof Iain McInnes reviews two papers this month, and discusses the increased risk of HZ infection with upadacitinib, as well as the role of the JAK-STAT pathway in SpA pathenogenesis. Keep-up to date with the latest in arthritis and cytokine signalling with Prof Iain McInnes. Everything discussed is available in a more detailed slide format in the publications section at cytokinesignalling.com.

Professor Roy Fleishmann, clinical professor of medicine at the University of Texas Southwestern Medical Center. Join Professor Peter Nash as he interviews authors of recent notable papers in rheumatology. In this edition, Professor Roy Fleishmann discusses the effect of baricitinib on inhibiting radiographic progression of structural joint damage over 5 years in patients with active RA.

Grace Wright presents the Day 4 highlights of the key abstracts and posters presented at ACR 2021.

Professor Leonard Calabrese presents the Day 3 highlights of the key abstracts and posters presented at ACR 2021.

Grace Wright presents the Day 2 highlights of the key abstracts and posters presented at ACR 2021.

Prof Iain McInnes discusses the risk of herpes zoster in RA patients taking biologics and DMARDS. He also discusses reactivation of hepatitis B in patients with RA taking tofacitinib. Keep-up to date with the latest in arthritis and cytokine signalling with Prof Iain McInnes. Everything discussed is available in a more detailed slide format in the publications section at cytokinesignalling.com.

Prof Calabrese presents the Day 1 highlights of the key abstracts and posters presented at ACR 2021.

A preview of the latest research at ACR 2021. Prof Ritchlin highlights important abstracts in cytokine signalling at the upcoming ACR Convergence.

Paul Bird, Conjoint Professor at the University of South Wales. Join Professor Peter Nash as he interviews authors of recent notable papers in rheumatology. In this edition, Dr Paul Bird assess the real‑world evaluation of effectiveness, persistence, and usage patterns of monotherapy and combination therapy tofacitinib in treatment of rheumatoid arthritis in Australia.

Prof Iain McInnes discusses poor prognostics factors from the FINCH 3 study, and the effectiveness and persistence of monotherapy and combination therapy from the Australian OPAL study. Keep-up to date with the latest in arthritis and cytokine signalling with Prof Iain McInnes. Everything discussed is available in a more detailed slide format in the publications section at cytokinesignalling.com.